Fujifilm Biotechnologies is expanding its biomanufacturing facilities, including a new quality control lab in Denmark and an iPSC development center in Wisconsin, while also investing heavily in AI integration across operations. This expansion supports increased production capacity and enhances operational efficiency, crucial for meeting the growing demand from pharmaceutical clients and ensuring supply chain resilience. Additionally, other major CDMOs like Lonza and MilliporeSigma are also enhancing their facilities globally to support biopharma growth and customer needs. Samsung Biologics has entered the U.S. market with its acquisition of a former GSK site in Maryland, further solidifying its global presence. These expansions underscore the industry's focus on technological advancement and geographic diversification to meet rising demand and regulatory requirements.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
